Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP)

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result